Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
epratuzumab · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| epratuzumab | DRUG | - |
* Diagnosis of relapsed or refractory low-grade, CD20+, B-cell NHL \* Received and failed at least 1 prior regimen of chemotherapy \* Rituximab-naive or received prior rituximab in their last treatment (single agent or in combination with chemotherapy) and demonstrated a time to progression of at le...
Epratuzumab is an investigational monoclonal antibody being studied for the treatment of non-Hodgkin's lymphoma, specifically low-grade forms of the disease. It is in Phase 2 clinical development and is not approved for commercial use. Amgen Inc. (ticker: AMGN) is the developer.
Epratuzumab targets CD22, a protein found on the surface of B cells. As a monoclonal antibody, it binds to CD22 and is designed to inhibit B-cell activity, which is relevant in B-cell malignancies such as non-Hodgkin's lymphoma. The target class is an inhibitor.
Epratuzumab is being developed by Amgen Inc., which trades under the ticker AMGN. Amgen is the company responsible for the clinical program in non-Hodgkin's lymphoma.
Epratuzumab is in Phase 2 clinical development for non-Hodgkin's lymphoma. It is an investigational therapy and has not been approved by the FDA. The development program includes one completed Phase 2 trial.
Epratuzumab has been studied in one completed Phase 2 trial, NCT00044902, titled "Monoclonal Antibody Treatment for Non-Hodgkin's Lymphoma (Low-Grade)." The trial enrolled adults 18 years and older and was uncontrolled, with no randomization or blinding. It is now completed.